Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease?
about
Recent advances in autosomal-dominant polycystic kidney disease.Efficacy of oral tolvaptan versus 3% hypertonic saline for correction of hyponatraemia in post-operative patients.Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment.Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema.Canonical Wnt inhibitors ameliorate cystogenesis in a mouse ortholog of human ADPKD.Clinical Features of 167 Inpatients with Autosomal Dominant Polycystic Kidney Disease at a Single Center in China
P2860
Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Will introduction of tolvaptan ...... ant polycystic kidney disease?
@en
type
label
Will introduction of tolvaptan ...... ant polycystic kidney disease?
@en
prefLabel
Will introduction of tolvaptan ...... ant polycystic kidney disease?
@en
P356
P1433
P1476
Will introduction of tolvaptan ...... ant polycystic kidney disease?
@en
P2093
Shigeo Horie
P2888
P356
10.1038/KI.2015.143
P407
P577
2015-07-01T00:00:00Z
P5875
P6179
1043698091